Results 91 to 100 of about 1,454 (181)

CGRP receptor antagonists. an expanding drug class for acute migraine?

, 2012
Introduction: Migraine afflicts approximately 11% of the population worldwide producing substantial disability, resulting in loss of productivity both at home and at the workplace. Calcitonin gene-related peptide (CGRP) is closely involved in the cascade
Luana Lionetto, MARTELLETTI, Paolo, NEGRO, ANDREA, SIMMACO, Maurizio   +3 more
core   +1 more source

Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives

, 2020
Introduction: Calcitonin Gene-Related Peptide (CGRP) has gradually emerged as a suitable therapeutic target to treat migraine. Considering the social and economic burden of migraine, it is fundamental to optimize the disease management with efficacious ...
Martelletti P., Sacco S., Spuntarelli V., Guglielmetti M., De Matteis E., Ornello R.   +5 more
core   +1 more source

New migraine prophylactic drugs:Current evidence and practical suggestions for non-responders to prior therapy

, 2023
Background: Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP(-R) mAbs) and small-molecule CGRP receptor antagonists (gepants) are new mechanism-based prophylactic drugs developed to address the unmet needs ...
Reuter, Uwe, Lee, Mi Ji, Al-Karagholi, Mohammad Al Mahdi   +2 more
core   +1 more source

A focus on quality of life and a swift return to normal activities for migraine sufferers

Неврология, нейропсихиатрия, психосоматика
Migraine ranks second among all conditions in terms of its impact on quality of life and work capacity, and is the leading cause of disability among people under the age of 50. Triptans, which have long been the mainstay of acute treatment, have a number
Yu. E. Azimova
doaj   +1 more source

Gepants [PDF]

Headache: The Journal of Head and Face Pain, 2020
openaire   +2 more sources

Lasmiditan as the First and Only Representative of a New Class of Neuroactive Anti-Migraine Medications: A Review

Безопасность и риск фармакотерапии
INTRODUCTION. Lasmiditan, a new selective 5-HT1F receptor agonist (approved by FDA in 2019), relieves migraine attacks via neuronal inhibition and acts in the central and peripheral nervous systems.
I. A. Mazerkina, R. N. Alyautdin
doaj   +1 more source

CGRP – a target for acute therapy in migraine: Clinical data

, 2018
Background A better understanding of the mechanisms underlying the migraine attack has reinforced the concept that migraine is a complex brain disease, and has paved the way for the development of new migraine specific acute treatments.
Peter J Goadsby, Roberta Messina, Goadsby, Peter J.; id_orcid, Messina R, Messina, Roberta, Goadsby PJ   +5 more
core   +1 more source

Blocking CGRP in migraine patients – a review of pros and cons

The Journal of Headache and Pain, 2017
Migraine is the most prevalent neurological disorder worldwide and it has immense socioeconomic impact. Currently, preventative treatment options for migraine include drugs developed for diseases other than migraine such as hypertension, depression and ...
Marie Deen, Edvige Correnti, Katharina Kamm, Tim Kelderman, Laura Papetti, Eloisa Rubio-Beltrán, Simone Vigneri, Lars Edvinsson, Antoinette Maassen Van Den Brink, On behalf of the European Headache Federation School of Advanced Studies (EHF-SAS)   +9 more
doaj   +1 more source

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases

Frontiers in Pharmacology
BackgroundThis study aimed to investigate the real-world profile of adverse events (AEs) associated with gepant medications in the clinical treatment of migraines by analyzing data collected from the VigiAccess database and the U.S.
Qiaofang Liang, Xiaolin Liao, Hongwen Wu, Yushen Huang, Taolin Liang, Hailong Li, Hailong Li, Hailong Li   +7 more
doaj   +1 more source

Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)

The Journal of Headache and Pain
Background Rimegepant, a novel oral calcitonin gene-related peptide receptor antagonist, has been recently approved for the acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, no data is available regarding real-life
Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, Francesco Casillo, Antonio Russo, Marcello Silvestro, Francesca Pistoia, Giorgio Dalla Volta, Matteo Cortinovis, Alberto Chiarugi, Danilo Antonio Montisano, Maria Pia Prudenzano, Sabina Cevoli, Edoardo Mampreso, Gianluca Avino, Marina Romozzi, Mariarosaria Valente, Carla Fasano, Stefania Battistini, Antonio Granato, Elisa Maria Piella, Innocenzo Rainero, Raffaele Ornello, Roberto De Icco, On behalf of the Italian Headache Registry (RICe) Study Group   +24 more
doaj   +1 more source